Financial Performance - The company expects a net profit attributable to shareholders to be between 5.5 million to 6 million CNY, representing a decrease of approximately 53.15% to 48.89% compared to the previous year's net profit of 11.73 million CNY[4] - The performance forecast is based on preliminary calculations and has not been audited, with final figures to be disclosed in the 2024 annual report[6] Sales Expenses - Sales expenses are estimated to be 45.6753 million CNY, an increase of 56.95% compared to the same period last year, significantly impacting net profit[4] - The increase in sales expenses is attributed to the expansion of overseas subsidiaries and the introduction of sales talent, leading to higher promotional and labor costs[5] - The company has seen an increase in sales revenue from Amazon, which has resulted in higher platform and sales expenses[5]
锦好医疗(872925) - 2024 Q4 - 年度业绩预告